c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential
Investing.com | Oct 8, 2026 4:04 AM EDT
Read original article